Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Loncastuximab tesirine: a novel antibody-drug conjugate for DLBCL

Carmelo Carlo-Stella • 21 Jun 2020
EHA 2020
Aggressive & Diffuse Large B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies Loncastuximab tesirine

Carmelo Carlo-Stella, MD, PhD, of Humanitas Clinical and Research Center, Rozzano, Italy, discusses initial results of a Phase II study of loncastuximab tesirine, a novel antibody-drug conjugate targeting CD19, in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Carmelo Carlo-Stella

2:21
Important practical considerations for the use of glofitamab for DLBCL
Carmelo Carlo-Stella • 20 Oct 2023
5:30
Glofitamab in R/R DLBCL: updated safety and efficacy data
Carmelo Carlo-Stella • 20 Oct 2023
7:13
Efficacy and safety of glofitamab for patients with Richter’s transformation
Carmelo Carlo-Stella • 15 Jun 2023
2:33
Glofitamab as a single agent in heavily pretreated patients with DLBCL
Carmelo Carlo-Stella • 15 Jun 2023

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals